An epidemiological perspective of personalized medicine: The Estonian experience

Journal of Internal Medicine

Volumn 277, Issue 2, 2015, Pages 188-200

  Milani, L ^a   Leitsalu, L ^a,b   Metspalu, A ^a,b  

^a UNIVERSITY OF TARTU   (Estonia)

^b UNIVERSITY OF TARTU   (Estonia)

Author keywords

Biobanks; eHealth; Electronic medical records; Estonia; Genomic medicine; Personalized medicine

Indexed keywords

ARTICLE; BIOBANK; BREAST CANCER; CARDIOVASCULAR DISEASE; ELECTRONIC MEDICAL RECORD; EPIDEMIOLOGY; ESTONIA; GENETIC ASSOCIATION; HEALTH CARE; HEALTH CARE FACILITY; HUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RISK FACTOR; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; FEMALE; GENETIC SCREENING; GENETICS; GENOMICS; MOLECULAR EPIDEMIOLOGY; TRENDS;

BIOLOGICAL SPECIMEN BANKS; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; ELECTRONIC HEALTH RECORDS; ESTONIA; FEMALE; GENETIC TESTING; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HUMANS; MOLECULAR EPIDEMIOLOGY; PRECISION MEDICINE;

EID: 84921494326     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12320     Document Type: Article

References (86)

1. EuroBioForum. Personalised Medicine Observatory. http://www.eurobioforum.eu/2028/observatory/#!/filter/filter_eucountries.
2. Abrahams E, Ginsburg GS, Silver M. The Personalized Medicine Coalition: goals and strategies. Am J Pharmacogenomics 2005; 5: 345-55.
3. Frank L. Biotechnology in the Baltic. Nat Biotechnol 2001; 19: 513-5.
4. Riigikogu. Human Genes Research Act. https://www.riigiteataja.ee/en/eli/531102013003/consolide 2000.
5. e-Health. Overview of Estonian Electronic Health Record (EHR) System. http://www.e-tervis.ee/index.php/en/news-and-arcticles/432-overview-of-estonian-electronic-health-record-ehr-system.
6. Guttmacher AE, Collins FS. Genomic medicine-a primer. N Engl J Med 2002; 347: 1512-20.
7. Yuille M, van Ommen G-J, Bréchot C et al. Biobanking for Europe. Brief Bioinform 2008; 9: 14-24.
8. BBMRI. Biobanking and Biomolecular Resources Research. http://bbmri.eu/.
9. Reichel J, Lind A-S, Hansson MG, Litton J-E. ERIC: a new governance tool for Biobanking. Eur J Hum Genet 2014; 22: 1055-7.
10. P3G. Public Population Project in Genomics and Society. http://p3g.org/.
11. Knoppers BM, Fortier I, Legault D, Burton P. The Public Population Project in Genomics (P3G): a proof of concept? Eur J Hum Genet 2008; 16: 664-5.
12. Harris JR, Burton P, Knoppers BM et al. Toward a roadmap in global biobanking for health. Eur J Hum Genet 2012; 20: 1105-11.
13. Leitsalu L, Haller T, Esko T et al. Cohort Profile: Estonian Biobank of the Estonian Genome Center, University of Tartu. Int J Epidemiol 2014; doi: 10.1093/ije/dyt268.
14. Soininen P, Kangas AJ, Würtz P et al. High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. Analyst 2009; 134: 1781-5.
15. Thorisson GA, Smith AV, Krishnan L, Stein LD. The International HapMap Project Web site. Genome Res 2005; 15: 1592-3.
16. Visscher PM, Brown MA, McCarthy MI, Yang J. Five years of GWAS discovery. Am J Hum Genet 2012; 90: 7-24.
17. NHGRI Division of Genomic Medicine. Catalog of Published Genome-Wide Association Studies. http://www.genome.gov/gwastudies/.
18. Welter D, MacArthur J, Morales J et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res 2014; 42: D1001-6.
19. Bernstein BE, Birney E, Dunham I, Green ED, Gunter C, Snyder M. An integrated encyclopedia of DNA elements in the human genome. Nature 2012; 489: 57-74.
20. Schaub MA, Boyle AP, Kundaje A, Batzoglou S, Snyder M. Linking disease associations with regulatory information in the human genome. Genome Res 2012; 22: 1748-59.
21. Maurano MT, Humbert R, Rynes E et al. Systematic localization of common disease-associated variation in regulatory DNA. Science 2012; 337: 1190-5.
22. Trynka G, Sandor C, Han B et al. Chromatin marks identify critical cell types for fine mapping complex trait variants. Nat Genet 2013; 45: 124-30.
23. Fu J, Wolfs MGM, Deelen P et al. Unraveling the regulatory mechanisms underlying tissue-dependent genetic variation of gene expression. PLoS Genet 2012; 8: e1002431.
24. Fairfax BP, Makino S, Radhakrishnan J et al. Genetics of gene expression in primary immune cells identifies cell type-specific master regulators and roles of HLA alleles. Nat Genet 2012; 44: 502-10.
25. Raj T, Rothamel K, Mostafavi S et al. Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science 2014; 344: 519-23.
26. van der Sijde MR, Ng A, Fu J. Systems genetics: from GWAS to disease pathways. Biochim Biophys Acta 2014; 1842: 1903-9.
27. Willer CJ, Schmidt EM, Sengupta S et al. Discovery and refinement of loci associated with lipid levels. Nat Genet 2013; 45: 1274-83.
28. Freathy RM, Timpson NJ, Lawlor DA et al. Common variation in the FTO gene alters diabetes-related metabolic traits to the extent expected given its effect on BMI. Diabetes 2008; 57: 1419-26.
29. Frayling TM, Timpson NJ, Weedon MN et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007; 316: 889-94.
30. Musunuru K, Strong A, Frank-Kamenetsky M et al. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature 2010; 466: 714-9.
31. Dimas AS, Lagou V, Barker A et al. Impact of type 2 diabetes susceptibility variants on quantitative glycemic traits reveals mechanistic heterogeneity. Diabetes 2014; 63: 2158-71.
32. Flannick J, Thorleifsson G, Beer NL et al. Loss-of-function mutations in SLC30A8 protect against type 2 diabetes. Nat Genet 2014; 46: 357-63.
33. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005; 37: 161-5.
34. Sullivan D, Olsson AG, Scott R et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012; 308: 2497-506.
35. Chimienti F, Devergnas S, Pattou F et al. In vivo expression and functional characterization of the zinc transporter ZnT8 in glucose-induced insulin secretion. J Cell Sci 2006; 119: 4199-206.
36. Sladek R, Rocheleau G, Rung J et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007; 445: 881-5.
37. Kanoni S, Nettleton JA, Hivert M-F et al. Total zinc intake may modify the glucose-raising effect of a zinc transporter (SLC30A8) variant: a 14-cohort meta-analysis. Diabetes 2011; 60: 2407-16.
38. Lalloo F, Evans DG. Familial breast cancer. Clin Genet 2012; 82: 105-14.
39. Evans DG, Shenton A, Woodward E, Lalloo F, Howell A, Maher ER. Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer 2008; 8: 155.
40. Mavaddat N, Peock S, Frost D et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 2013; 105: 812-22.
41. Wang X, Pankratz VS, Fredericksen Z et al. Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Hum Mol Genet 2010; 19: 2886-97.
42. Antoniou AC, Beesley J, McGuffog L et al. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res 2010; 70: 9742-54.
43. Johnston JJ, Rubinstein WS, Facio FM et al. Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes. Am J Hum Genet 2012; 91: 97-108.
44. Dorschner MO, Amendola LM, Turner EH et al. Actionable, pathogenic incidental findings in 1, 000 participants' exomes. Am J Hum Genet 2013; 93: 631-40.
45. Michailidou K, Hall P, Gonzalez-Neira A et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 2013; 45: 353-61, 361e1-2.
46. Tikkanen E, Havulinna AS, Palotie A, Salomaa V, Ripatti S. Genetic risk prediction and a 2-stage risk screening strategy for coronary heart disease. Arterioscler Thromb Vasc Biol 2013; 33: 2261-6.
47. Véron A, Blein S, Cox DG. Genome-wide association studies and the clinic: a focus on breast cancer. Biomark Med 2014; 8: 287-96.
48. Pashayan N, Guo Q, Pharoah PDP. Personalized screening for cancers: should we consider polygenic profiling? Per Med 2013; 10: 10.2217/pme.13.46.
49. Pashayan N, Duffy SW, Chowdhury S et al. Polygenic susceptibility to prostate and breast cancer: implications for personalised screening. Br J Cancer 2011; 104: 1656-63.
50. Yarwood A, Han B, Raychaudhuri S et al. A weighted genetic risk score using all known susceptibility variants to estimate rheumatoid arthritis risk. Ann Rheum Dis 2013; doi: 10.1136/annrheumdis-2013-204133
51. Klimentidis YC, Wineinger NE, Vazquez AI, de Los Campos G. Multiple metabolic genetic risk scores and type 2 diabetes risk in three racial/ethnic groups. J Clin Endocrinol Metab 2014; 99: E1814-8.
52. Vaxillaire M, Yengo L, Lobbens S et al. Type 2 diabetes-related genetic risk scores associated with variations in fasting plasma glucose and development of impaired glucose homeostasis in the prospective DESIR study. Diabetologia 2014; 57: 1601-10.
53. Fritsche LG, Chen W, Schu M et al. Seven new loci associated with age-related macular degeneration. Nat Genet 2013; 45: 433-9, 439e1-2.
54. Malik R, Bevan S, Nalls MA et al. Multilocus genetic risk score associates with ischemic stroke in case-control and prospective cohort studies. Stroke 2014; 45: 394-402.
55. Do CB, Hinds DA, Francke U, Eriksson N. Comparison of family history and SNPs for predicting risk of complex disease. PLoS Genet 2012; 8: e1002973.
56. Fischer K, Kettunen J, Würtz P et al. Biomarker profiling by nuclear magnetic resonance spectroscopy for the prediction of all-cause mortality: an observational study of 17, 345 persons. PLoS Med 2014; 11: e1001606.
57. Zilina O, Teek R, Tammur P et al. Chromosomal microarray analysis as a first-tier clinical diagnostic test: Estonian experience. Mol Genet genomic Med 2014; 2: 166-75.
58. Yang Y, Muzny DM, Reid JG et al. Clinical whole-exome sequencing for the diagnosis of mendelian disorders. N Engl J Med 2013; 369: 1502-11.
59. Topol EJ. Individualized medicine from prewomb to tomb. Cell 2014; 157: 241-53.
60. Green RC, Berg JS, Grody WW et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013; 15: 565-74.
61. NHGRI. National Human Genome Research Institute. http://www.genome.gov/10001634.
62. Academy of Medical Sciences. Realising the potential of stratified medicine. 2013.
63. PHG Foundation. Public Health Genomics Foundation. http://www.phgfoundation.org/impact/genomic_medicine_uk.
64. EAPM. European Alliance for Personalised Medicine. http://euapm.eu/.
65. Global Alliance. Global Alliance for Genomics and Health. http://genomicsandhealth.org/about-global-alliance.
66. CDC Office of Public Health Genomics. Genomic Tests and Family History by Levels of Evidence. http://www.cdc.gov/genomics/gtesting/tier.htm.
67. IPM. Icahn School of Medicine at Mount Sinai. http://icahn.mssm.edu/research/institutes/institute-for-personalized-medicine/about-ipm.
68. Gottesman O, Kuivaniemi H, Tromp G et al. The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future. Genet Med 2013; 15: 761-71.
69. Reformierakond. Reformierakonna esimehe, peaminister Andrus Ansipi kõne erakonna Üldkogul Tartus 25. mail. http://www.reform.ee/uudised/reformierakonna-esimehe-peaminister-andrus-ansipi-kone-erakonna-uldkogul-tartus-25-mail 2013.
70. Eesti Arstide Päevad. Personaalne meditsiin, Tanel Ross. http://www.haigekassa.ee/uploads/userfiles/20140404Personaalne_meditsiin_EAP.pdf 2014.
71. Estonian Government. Coalition agreement 2014. https://valitsus.ee/sites/default/files/content-editors/failid/2014_coalition_agreement_0.pdf
72. Bousquet J, Anto JM, Sterk PJ et al. Systems medicine and integrated care to combat chronic noncommunicable diseases. Genome Med 2011; 3: 43.
73. Leitsalu L, Hercher L, Metspalu A. Giving and Withholding of Information following Genomic Screening: challenges Identified in a Study of Primary Care Physicians in Estonia. J Genet Couns 2011; 21: 591-604.
74. Tiik M, Ross P. Patient opportunities in the Estonian Electronic Health Record System. Stud Health Technol Inform 2010; 156: 171-7.
75. Morris AP, Voight BF, Teslovich TM et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet 2012; 44: 981-90.
76. DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium; Asian Genetic Epidemiology Network Type 2 Diabetes (AGEN-T2D) Consortium; South Asian Type 2 Diabetes (SAT2D) Consortium; Mexican American Type 2 Diabetes (MAT2D) Consortium; Type 2 Dia MA. Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet 2014; 46: 234-44.
77. Speliotes EK, Willer CJ, Berndt SI et al. Association analyses of 249, 796 individuals reveal 18 new loci associated with body mass index. Nat Genet 2010; 42: 937-48.
78. Teslovich TM, Musunuru K, Smith AV et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010; 466: 707-13.
79. Lango Allen H, Estrada K, Lettre G et al. Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature 2010; 467: 832-8.
80. Barrett JC, Clayton DG, Concannon P et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 2009; 41: 703-7.
81. Groop L, Pociot F. Genetics of diabetes-are we missing the genes or the disease? Mol Cell Endocrinol 2014; 382: 726-39.
82. Orozco G, Viatte S, Bowes J et al. Novel rheumatoid arthritis susceptibility locus at 22q12 identified in an extended UK genome-wide association study. Arthritis Rheumatol (Hoboken, NJ) 2014; 66: 24-30.
83. Eyre S, Bowes J, Diogo D et al. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet 2012; 44: 1336-40.
84. Jostins L, Ripke S, Weersma RK et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491: 119-24.
85. Ripke S, Neale BM, Corvin A et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014; 511: 421-7.
86. Mühleisen TW, Leber M, Schulze TG et al. Genome-wide association study reveals two new risk loci for bipolar disorder. Nat Commun 2014; 5: 3339.